IntroductIon
Cardiovascular disease (CVD) is the most common underlying cause of death in the world, accounting for an estimated 31% of all global deaths. By 2030, 44% of the US adult population is projected to have some form of CVD. 1 Although death rates attributable to CVD declined 40% between 1980 and 2000 2 and 25% from 2004 to 2014 1 in the USA, the incidence and prevalence continue to increase. 3 In addition, CVD accounts for a significant burden of morbidity and health expenditures in the USA. 4 As such, a public health priority is to develop precise risk assessment tools and cost-effective prevention and therapeutic strategies. While traditional risk factors for CVD (comprising age, sex, race, hypertension, dyslipidaemia, smoking and diabetes) predominantly account for the risk of developing coronary artery disease (CAD), 5 6 they are less useful in predicting patient outcomes among those who already have CAD (c-statistic for 10-year CVD risk ≈ 0.82 vs c-statistic for secondary cardiovascular events ≈ 0.62). 7 8 Novel biomarkers and genetic profile may better address the deficiencies in risk assessment. There is an urgent and compelling need for identifying novel biomarkers and for developing precise diagnostic tests to better risk stratify patients with established CAD in order to improve disease management strategies.
CAD has a complex multifactorial aetiology. The development of coronary atherosclerosis is a consequence of genetic susceptibility, environmental exposures and interactions between risk factors on many levels. Susceptibility to CAD varies extensively between subjects and may be partly attributed to genomic and epigenetic variations. Moreover, environmental, behavioural and psychosocial factors have a substantial impact on the incidence and progression of CAD. Importantly, atherosclerosis can be viewed as a progressive disease with a subclinical Open Access Over the years, the size of EmCAB continued to grow with 7000 unique patients recruited to date. The current EmCAB data set contains full information on clinical variables including detailed family history and psychosocial factors obtained by questionnaires and data extracted from electronic health records on the entire population. In various subsets of the dataset, we have vascular function measures, outcomes, genomics, protein biomarkers, regenerative markers, transcriptomic analysis, metabolomics profiling and longitudinal follow-up for adverse cardiovascular outcomes. The rich and complex data available in EmCAB provide unparalleled opportunities for conduct of integrative analysis of various important, unsolved research questions, such as -omic signatures for CAD severity, novel predictors for disease progression and for incident cardiovascular events.
cohort descrIPtIon All patients aged 18 years and older undergoing cardiac catheterisation at three Emory Healthcare sites in Atlanta are asked to participate in this prospective registry. Patients are excluded if they have congenital heart disease, severe valvular heart disease, severe anaemia, a recent blood transfusion, myocarditis, history of active inflammatory disease, cancer or are unable or not willing to provide consent (approximately 5%). The study was approved by the institutional review board (IRB) at Emory University (Atlanta, Georgia, USA) and is renewed annually. All participants provided written informed consent at the time of enrolment. Specimens and data continue to be added to the EmCAB as new subjects are consented on an almost daily basis. To facilitate future research, the biobank has IRB approval for future testing of biospecimens and analysis of de-identified data. Table 1 summarises the patient characteristics in this cohort. The mean age at enrolment was 63. Approximately two thirds were male, 72% white, 24% black, 2% Asian and 1% Hispanic. While 75% of them had obstructive coronary artery disease (defined as >50% luminal narrowing in a major epicardial vessel) at enrolment, 11% had normal (<10% stenosis) coronary angiograms. About 25% had a history of previous MI, 8% presented with an acute MI and 36% had a history of heart failure. Most (44%) were retired, 34% were employed, 16% disabled and 6% unemployed. About 51% were high school graduates with/without some college education, and 36% had a college degree (16% received graduate education). The majority (67%) were married; 25% were widowed, divorced or separated; and 8% were never married.
Follow-up measures
Follow-up phone interview is conducted by trained study personnel, and the calls are planned to be made at 1 and 5 years after initial enrolment. The actual follow-up time periods range up to 12 years because of limited resources. Adverse CVD events, including death, non-fatal MI, acute coronary syndromes, heart failure, hospitalisations, cardiac procedures (eg, revascularisation), strokes and peripheral arterial disease events are recorded. If a patient has experienced a major CVD event such as cardiovascular death, MI, hospitalisations or stroke, medical records are used for verification. When a study participant has died, the study personnel gather information from multiple sources to confirm the event and the time of the event. Social security death index, state records, obituaries, hospital records and death certificates are queried, and family members are contacted to obtain details. An Events Adjudication Committee designates final arbitration of all cardiovascular events and adjudicates the cause of death.
Additional information is collected on follow-up coronary angiogram data, development of comorbidities (hypertension, diabetes, cardiac arrhythmia, valvular heart disease, obstructive sleep apnoea and cancer) and changes in medications (aspirin, Plavix, beta blocker, calcium channel blocker, angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB), aldosterone antagonist, diuretics, nitrates, lipid-lowering agents, anticoagulants). Furthermore, detailed questionnaires are collected to assess for depression (Patient Health Questionnaire 9), angina frequency (Seattle Angina Questionnaire), physical activity (Duke Activity Status Index), functional status (New York Heart Association classification) and smoking status.
Major adverse event rate (for all-cause death or MI) is 6.4% in 1 year and 13% in 3 years, and approximately 1500 major events have been recorded. All event rates including revascularisation are 17% in 1 year and 25% in 3 years, for a total of approximately 3000 events to date. Figure 1 displays the cumulative incidence over time for each of the major cardiovascular events. Approximately 96% of patients have follow-up data for a median follow-up time of 3.5 years (IQR: 1.7-6.7 years), with a 3.3% refusal rate for continued follow-up. These patients tend to be healthier (hypertension 72% vs 79%, P=0.01; diabetes 29% vs 35%, P=0.05; dyslipidaemia 65% vs 71%, P=0.04; obstructive CAD 70% vs 77%, P=0.02; history of heart failure 29% vs 37%, P=0.02), compared with the group who agree to be contacted. Also, more of these patients have full-time jobs (36% vs 29%, P=0.01).
study measures
At enrolment, patients are interviewed to collect information on demographic characteristics, medical history, detailed family history, medication usage, health behaviours (alcohol/drug use), sleep quality, menstrual history, psychological factors and neuropsychological functioning prior to cardiac catheterisation. In addition, medical records are reviewed by study personnel to confirm self-reported history of MI and other chronic conditions as well as to document previous angiographic findings and coronary revascularisation history. Laboratory data collection includes sodium, potassium, creatinine, albumin, B-type natriuretic peptide, blood urea nitrogen, haemoglobin, glucose, HbA1c (glycated haemoglobin), complete blood count, serum lipid profile.
Comprehensive angiographic results at the time of enrolment are recorded. Furthermore, subjects are followed at 1 and 5 years. To date, detailed follow-up data (as described above) are available from 96% of the patients.
Additional blood samples used to obtain biochemical data (ie, DNA, RNA, progenitor cells, proteomics, metabolomics and biomarker assays) are collected by a nurse or physician from the arterial catheter inserted for cardiac catheterisation before administration of anticoagulants after an overnight fasting, and stored in Paxgene tubes (QIAGEN, San Diego, California, USA) at −80°C. These data are available in subsets of patients; specifically, we have conducted high-resolution metabolomics analyses for >20 000 metabolites using liquid chromatography mass spectrometry (LC/MS) in 1500 EmCAB patients. Samples are analysed in triplicate by liquid chromatography-Fourier transform mass spectrometry (Accela-LTQ Velos Orbitrap; m/z range from 85 to 850) with 10 µL Open Access Oxidative stress markers CyS, CySS, GSH and GSSG Follow-up Adverse events Death, MI, heart failure, revascularisation, stroke CABG, coronary artery bypass graft surgery; CMV, cytomegalovirus; CyS, cysteine; CySS, cystine; FDP, fibrin degradation product; GSH, reduced glutathione; GSSG, oxidised glutathione; GWAS, genome wide association study; HbA1c, haemoglobin A1c; hs-CRP, high sensitivity C reactive proten; Hs-cTn, high sensitivity cardiac troponin; HSP70, heat shock protein-70; MI, myocardial infarction; PCI, percutaneou coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; SNP, single nucleotide polymorphism; suPAR, soluble urokinase-type plasminogen activator receptor.
injection volume using a dual chromatography setup (anion exchange and C18) and a formic acid/acetonitrile gradient. Extractions are performed with acetonitrile containing a mixture of internal standards and maintained in an autosampler maintained at 4°C until injection. Electrospray ionisation is used in the positive ion mode. Data are extracted using apLCMS 9 with modifications by xMSanalyzer 10 as m/z features, where an m/z feature is defined by m/z (mass-to-charge ratio), retention time and ion intensity (integrated ion intensity for the chromatographic peak). Identities of many of the m/z features are known from previous research using ion dissociation patterns by tandem mass spectrometry, coelution with authentic standards and cross-platform validation. Possible identities of other m/z features were obtained using the Metlin Mass Spectrometry Database and Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www. genome. jp/ kegg/ pathway. html) databases using a mass error threshold of 10 ppm (relative m/z error ×106).
A total of 105 candidate single nucleotide polymorphisms (SNPs) were analysed in a subset of up to 3488 participants and genome-wide genotyping (Illumina Multi-Ethnic Global array) in approximately 1300 patients. Gene expression data (Illumina HT-12 bead arrays) with 14 111 probes are available in 338 patients. We have performed extensive phenotyping of circulating progenitor cells (CD34+ cell subsets), a measure of endogenous regenerative capacity in >2000 patients. The availability of immunoassays and high-performance LC/MS has enabled the identification of inflammatory protein biomarkers. Circulating levels of the following protein biomarkers were measured in 3500-6000 participants: hs-cTn (high-sensitivity cardiac troponin), hs-CRP (high-sensitivity C reactive protein), suPAR (soluble urokinase-type plasminogen activator receptor), FDP (fibrin degradation product) and HSP-70 (heat shock proteins). High-sensitivity troponin-I was measured by Abbott Laboratories (Abbott Park, Illinois, USA). Serum CRP and FDP measurements are determined using a sandwich immunoassay by FirstMark, Division of GenWay Biotech (San Diego). Serum HSP-70 is measured with a sandwich ELISA (R&D Systems, Minneapolis, Minnesota, USA) and optimised by FirstMark. Plasma suPAR levels are measured using commercially available kits (suPARnostic kit; Virogates, Copenhagen, Denmark). Oxidative markers including plasma aminothiols, cysteine and glutathione and their oxidised counterparts are available in 1500 patients. Table 2 summarises the types of patient data available in the EmCAB database.
In addition to the data listed in table 2, Emory Clinical Data Warehouse provides abstraction of comprehensive and longitudinal electronic health record data of clinical characteristics, comorbidities and laboratory values (eg, blood pressure, body weight, HbA1c, urine protein and serum creatinine). Abstraction is possible for all visits before and after the enrolment date at Emory. Moreover, abstraction can be customised to obtain data in a specific time period depending on the research purposes. In summary, the large sample size combined with a high event rate in this cohort with CAD provides a unique opportunity to conduct CVD outcome studies to answer a variety of research questions that may not be possible in other population-based cohorts.
FIndIngs
The EmCAB has been used as a data resource for discovery of novel predictive factors (including biomarkers and molecular signatures) for clinical outcomes. Genomics: We demonstrated that the 9p21 risk locus promotes atherosclerosis and its progression in 2334 Caucasian patients enrolled in EmCAB. 11 Moreover, in 308 EmCAB patients who underwent two or more coronary angiograms at least 6 months apart, we measured the change in Gensini score over time and found an association between the rs10757278 SNP and CAD progression (P=0.023) with homozygotes for the risk variant having >3-fold greater odds of CAD progression compared with the wild-type group. Subsequently, a combined genetic risk score (GRS) based on 11 disease-associated SNPs was developed to predict adverse cardiovascular events. In 2597 EmCAB subjects, we identified cases with a history of MI onset at age<50 years and controls≥50 years old without prior MI. The analysis was repeated with 60 and 70 years old as cut points. The GRS was found to be significantly associated with prevalent MI (figure 2) and improved the c-statistic by up to 1.7%. 12 In addition, the EmCAB has involved in many large-scale genetic association studies, including finding variants for atherosclerosis, 13 14 CAD, [15] [16] [17] and mortality. 13 14 19 In recent years, the EmCAB has also participated in the GENIUS-CHD consortium, a global collaborative effort to evaluate the effect of genetic variation and identify determinants for subsequent coronary heart disease outcomes. Transcriptomics: We further explored peripheral blood gene expression profiles to assess its ability to predict acute MI and/or cardiovascular death. In 338 EmCAB subjects with CAD, we analysed gene expression using the Illumina HT-12 microarrays in two phases (discovery n=175 and replication n=163) and genome-wide association study was performed. There was significant differential expression between healthy and MI groups with overall downregulation of genes involved in T-lymphocyte signalling and upregulation of inflammatory genes. Expression quantitative trait loci analysis provided evidence for altered local genetic regulation of transcript abundance in MI samples. A first principal component (PC1) score derived from 10 transcripts that capture the covariance of 238 genes in the discovery Open Access phase significantly predicted risk of cardiovascular death in the replication and combined samples. The hazard was significantly higher for those with a low PC1 score compared with those with a high score and improved the c-statistic by 9% (P=0.03). 20 Protein biomarkers: The availability of immunoassays has enabled the identification of inflammatory protein biomarkers CRP, FDP, HSP-70 and suPAR as prognostic predictors of future risk of death and MI in patients with CAD. We combined these biomarkers into an aggregate biomarker risk score, calculated by adding one point for every elevated marker that stratifies the risk of major adverse events in approximately 3000 EmCAB patients ( figure 3) . 21 22 The results suggest the importance of activation of multiple pathophysiologic pathways, measured in the circulation, as directly impacting prognosis. Oxidative stress: We have also shown that a high burden of oxidative stress, measured as higher levels of cystine, lower levels of glutathione or altered ratios of oxidised to reduced aminothiols, is associated with cellular dysfunction, ageing, risk factors for CVD and with incident and MI in the 1411 EmCAB patients with CAD. 23 Circulating progenitor cells: Reduced circulating progenitor cell counts (CD34+ or CD34+/CD133+), indicating decreased reparative capacity, were found to be related to an elevated risk of death in these patients. 24 Importantly, CD34+/CD133+ cell counts improved risk prediction metrics beyond standard risk factors.
strengths And weAknesses
The goal of the EmCAB is to identify novel determinants of CVD progression and outcomes. The main advantages of this cohort include extensive collection of epidemiological and detailed clinical data, a large patient cohort from a single healthcare system that minimises treatment heterogeneity, and long-term follow-up information of patients' clinical data and outcomes. Most importantly, this patient population has coronary angiographic information on all enrolled subjects, is enriched for presence of CAD, and has high event rates for various major cardiovascular outcomes that provide ample statistical power for studies of secondary risk prediction and prevention strategies. Furthermore, the availability of genetic and molecular profiling data provides opportunities to discover important features to improve prediction of clinical outcomes in the context of precision medicine. A potential weakness is that patients are only recruited from Emory Healthcare system and the results may not be generalisable to other patients with CAD. Another limitation is that available resources evolve over time, so not all data types are available among all patients. With the ultimate goal of recruiting a total of 12 000 EmCAB patients, the sample size for each data type continues to increase.
